Nivolumab in advanced lung cancer: Indication of major added benefit
Friday, August 19, 2016 - 08:31
in Health & Medicine
Patients with advanced nonsquamous NSCLC who have already undergone chemotherapy survive longer with the drug Nivolumab than with docetaxel.